3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Endocrine
3
NET
2
Gastrointestinal
1
Conditions
Gastrointestinal Stromal Tumors
31
Colorectal Neoplasms
12
Pancreatic Neoplasms
11
Carcinoma, Hepatocellular
11
Stomach Neoplasms
8
Neoplasms
7
Liver Neoplasms
7
Esophageal Neoplasms
6
Carcinoma, Renal Cell
6
Neoplasm Metastasis
5
Gastrointestinal Neoplasms
5
Adenoma, Islet Cell
5
Neuroendocrine Tumors
4
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Prostatic Neoplasms
3
Carcinoma
3
Thyroid Neoplasms
2
Sarcoma
2
Rectal Neoplasms
2
Neoplasms, Glandular and Epithelial
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Multiple Myeloma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Digestive System Neoplasms
2
Colonic Neoplasms
2
Adenoma
2
Adenocarcinoma Of Esophagus
2
Interventions
lanreotide
2
Temozolomide
2
Capecitabine
2
zimberelimab
1
veliparib
1
pembrolizumab
1
ganitumab
1
conatumumab
1
arginyllysine
1
Sunitinib
1
Rose Bengal
1
Quality of Life
1
Patient Reported Outcome Measures
1
Octreotide
1
Molecular Diagnostic Techniques
1
Immunotherapy
1
Everolimus
1
Drug Therapy
1
Biological Therapy
1
Bevacizumab
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoid Tumor
×
Sunitinib
×
Gastrointestinal
×
Clear all
NCT05477576
2026-03-30
ACTION-1
RayzeBio, Inc.
Phase 3
Recruiting
338 enrolled